| Professional Experience |
| 09/2008 - Present |
Borland-Groover Clinic, P.A.
Ormond Beach, Florida
Gastroenterologist |
| 07/1987 - 09/2008 |
Gastroenterology Consultants, P.A.
Ormond Beach, Florida
Gastroenterologist |
|
|
| Academic Appointments |
| 07/1976 - 06/1978 |
Oral Roberts University
Tulsa, Oklahoma
Instructor in Chemistry |
|
|
| Education |
| 1982 |
University of Oklahoma College
Oklahoma City, Oklahoma
Medical Doctor |
| 1977 |
Oral Roberts University
Tulsa, Oklahoma
Mathematics and Biology
Bachelor of Science |
|
|
| Post Graduate Training |
| 07/1982 – 06/1983 |
University of Oklahoma
Oklahoma City, Oklahoma
Intern, Internal Medicine |
| 07/1983 - 06/1985 |
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Resident, Internal Medicine |
| 07/1985 - 06/1987 |
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Fellow, Gastroenterology |
|
|
| Board Certification |
| 09/1986 |
American Board of Internal Medicine |
| 11/1987 |
American Board of Gastroenterology |
|
|
| Licensure |
| |
Florida Medical License |
| |
Federal DEA Registration |
|
|
| Hospital Affiliations |
| 07/1987 - Present |
Halifax Medical Center |
| 07/1987 - Present |
Florida Hospital - Ormond Memorial |
| 07/1987 - Present |
Florida Hospital - Flagler |
|
|
| Professional Associations |
| |
American Medical Association |
| |
Florida Medical Association |
| |
Volusia County Medical Association |
|
|
| Research Experience |
| |
Study to investigate the safety and Efficacy of Dexloxiglumide in Female Patients with Constipation-Predominant Irritable Bowel Syndrome. |
| |
A Multi-Center Study Comparing Treatment with Esomeprazole to Lansoprazole in Patients with Moderate or Severe Erosive Esophagitis. |
| |
A Muti-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Crohn’s Disease. |
| |
A Phase Three, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Efficacy and Safety of OPC-6535 Tablets in the Treatment of Subjects with Active Ulcerative Colitis. |
| |
A Phase Three, Multi-Center, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC 6535 Oral Tablets and 800mg BID of Asacol in the Maintenance of Remission in Subjects with Ulcerative Colitis. |
| |
A Phase Three, Multi-Center, 52-Week, Open-Label, Extension Study of the Safety and Efficacy of 25mg or 50mg of OPC-6535 Oral Tablets in the Treatment of Subjects with Ulcerative Colitis. |
| |
A 6-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study, to Assess the Efficacy and Safety of Oral Tegaserod (6mg BID) and Placebo in Female Patients with Dyspepsia. |
| |
A One-Year, Open Label, Multi-Center, and Extension Study to Assess the Long-Term Safety of Tegaserod 6mg BID Given Orally in Female patients with Symptoms of Dyspepsia. |
|
|
